Unit
Immunity and Cancer (U932)
Thematic areas of research:
Image
To top
Unit
ANA-MARIA LENNON / OLIVIER LANTZ
Immunity and Cancer (U932)
Created in 2005, the INSERM U932 Unit is composed of 10 teams, spread over two buildings (Hôpital Curie and Constant-Burg building, rue Lhomond), with a total of about 120 people.
Teams
Key figures
334
publication since 2017
6
ERC since 2008
3
start-ups
Key publications
All publications
-
-
-
-
Constitutive Siglec-1 expression confers susceptibility to HIV-1 infection of human dendritic cell precursorsProceedings of the National Academy of Sciences
-
-
Rab6-dependent retrograde traffic of LAT controls immune synapse formation and T cell activationJournal of Experimental Medicine
-
-
News
All news
-
Ana-Maria Lennon-Duménil, lauréate d’un ERC Advanced Grant
Le Conseil européen de la recherche (ERC) a annoncé le 26 avril 2022 les lauréats des prestigieux « ERC Advanced Grants ». Parmi les quatre Français sélectionnés en sciences de la vie : Ana-Maria Lennon-Duménil, chercheuse de renommée internationale en immunologie pour son projet qui explore un mécanisme inédit de certaines cellules immunitaires dans l’équilibre intestinal.26/04/2022 -
Mieux connaître les cellules dendritiques pour mieux combattre le cancer
A l’Institut Curie, les médecins et chercheurs de l’unité Immunité et cancer (Institut Curie, Inserm) ont identifié pour la première fois deux archétypes de maturation des cellules dendritiques, cellules clefs pour initier les réponses immunitaires.
22/04/2022 -
Extracellular vesicles to fight triple-negative breast cancer
Triple-negative breast cancer is a tumor for which the search for new therapeutic solutions is crucial. Clotilde Théry’s team at Institut Curie has just shown for the first time, and unexpectedly, that extracellular vesicles in tumors induce macrophages that could promote anti-tumor responses.04/05/2022 -
Macrophage populations in breast cancer
In contrast to the current consensus, the presence of macrophages around breast cancer is not necessarily a bad sign, according to the work conducted by Eliane Piaggio’s Translational Immunotherapy team at Institut Curie. Biologists reveal a new population of macrophages that is associated to better prognosis for breast cancer patients. These results were published in the journal Cell on March 23, 2022.30/03/2022 -
Etudier les cellules souches pour comprendre les cellules cancéreuses
A partir du 1er décembre, Enzo Poirier intègre le Centre de recherche de l’Institut Curie au sein l’unité Immunité et cancer (U932) en tant que JPI (Junior Principal Investigator) de l’équipe nouvellement créée Immunité des cellules souches.20/12/2021 -
Des collaboratrices de l’Institut Curie rendent hommage aux 110 ans du 2e prix Nobel de Marie Curie
A l'occasion des 110 ans du 2e prix Nobel de Marie Curie le 10 décembre 2021 et le Jour J de la traditionnelle cérémonie de remise des prix à Stockholm, cinq chercheuses et médecins de l’Institut Curie ont répondu aux questions : « Que représente pour vous cette double distinction attribuée à la célèbre scientifique ? En quoi la figure de Marie Curie vous inspire-t-elle dans vos travaux et dans votre métier ? ».10/12/2021
Scientific events
All scientific events
21 Jun
2022
Seminar
11h-23h
Title soon
LamImSys Lab is interested in understanding the roles of nuclear envelope proteins, especially A-type lamins (lamin A/C) in the regulation of the development and functions of the cells of the immune system. We are studying these mechanisms not only at a basic level but also in the immune response against pathogens, in tumors and in inflammatory and autoimmune diseases.
7 Jun
2022
Seminar
11h-23h
Molecular regulation of T cell responses in human cancer
T cells can largely infiltrate human tumors but fail to provide long-term control of cancer growth due to acquired dysfunction and immunosuppression in the tumor microenvironment. We have discovered stem-like T cell populations with capability to mediate superior anti-tumor T cell responses. I will discuss the molecular properties of these cells in relation to dysfunctional mechanisms and immunosu
7 Jun
2022
Seminar
10h-23h
Dissecting and modulating reactive anti-tumor immunity in human cancers
Reinvigoration of tumor-specific T cells by cancer immunotherapies, in particular PD-1/PD-L1 blocking agents, has been the most important innovation in the treatment of patients with cancer. Nevertheless, durable clinical benefit is currently limited to a small number of patients. At present, the immunological alterations that occur in human cancers upon PD-1 blockade are not well understood. Usin
4 Apr
2022
Seminar Immunology series
11h-23h
Decoding the mode of action of tumor immunotherapies using intravital imaging
Understanding complex interactions between the immune system and the tumor microenvironment is an essential step towards the rational development and optimization of immunotherapies. Several experimental approaches are available to tackle this complexity but most are not designed to address the dynamic features of immune reactions, including cell migration, cellular interactions, and transient sig
28 Mar
2022
Seminar
11h-23h
Tuning of actin remodeling as driving force for the adaptable activities of T lymphocytes
The activation and function of T lymphocytes is determined by their ability to migrate and to assemble immunological synapses with antigen-presenting cells. Such dynamic properties are highly dependent on actin cytoskeleton remodeling. My research activity has focused on elucidating the molecular control of actin cytoskeleton remodeling in T lymphocytes via the prism of rare immunodeficiencies due
Job offers
All job offers
-
Technician or Engineer with experience in flow cytometry (M/F)
The Curie Institute Research Center
The “Institut Curie” is a major player in the research and fight against cancer. It consists of a hospital and a Research Center of more than 1000 employees with a strong international representativeness.
The objective of the Curie Institute Research Center is to develop basic research and to use the knowledge produced to improve the diagnosis, prognosis, and therapeutics of cancers as part of the continuum between basic research and innovation serving the patient.
-
Postdoctoral Position in Computational Onco-Immunology (M/F)The Curie Institute Research Center
The Institut Curie (http://www.institut-curie.org) is one of the biggest European institutions for cancer research with a strong interdisciplinary tradition. Institut Curie is located in the center of Paris in a rich scientific environment. It consists of a hospital and a Research Center of more than 1000 employees with a strong international representativeness.
The objective of the Curie Institute Research Center is to develop basic research and to use the knowledge produced to improve the diagnosis, prognosis, and therapeutics of cancers as part of the continuum between basic research and innovation serving the patient.